deucravacitinib
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Psoriasis Vulgaris
Conditions
Psoriasis Vulgaris
Trial Timeline
Oct 1, 2023 → Jun 1, 2026
NCT ID
NCT05858645About deucravacitinib
deucravacitinib is a approved stage product being developed by Bristol Myers Squibb for Psoriasis Vulgaris. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05858645. Target conditions include Psoriasis Vulgaris.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06979453 | Phase 3 | Recruiting |
| NCT07256015 | Pre-clinical | Recruiting |
| NCT06869551 | Phase 3 | Recruiting |
| NCT06725264 | Phase 2 | Withdrawn |
| NCT06701513 | Pre-clinical | Recruiting |
| NCT06512337 | Pre-clinical | Recruiting |
| NCT06566768 | Phase 1 | Completed |
| NCT06258668 | Pre-clinical | Recruiting |
| NCT06476834 | Approved | Completed |
| NCT05821374 | Phase 1 | Withdrawn |
| NCT06091956 | Phase 2 | Completed |
| NCT05858645 | Approved | Recruiting |
| NCT05946941 | Phase 3 | Active |
| NCT06104644 | Pre-clinical | Active |
| NCT05701995 | Approved | Completed |
| NCT05617677 | Phase 3 | Active |
| NCT05620407 | Phase 3 | Active |
| NCT05556265 | Phase 2 | Terminated |
| NCT05478499 | Approved | Completed |
| NCT04908202 | Phase 3 | Active |
Competing Products
20 competing products in Psoriasis Vulgaris
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo | Ventyx Biosciences | Phase 2 | 47 |
| LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous | Eli Lilly | Phase 2 | 52 |
| Ixekizumab | Eli Lilly | Phase 3 | 77 |
| 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + Baricitinib | Eli Lilly | Phase 2 | 52 |
| CT-P43 + Stelara | Celltrion | Phase 3 | 77 |
| CT-P17 + EU-approved Humira | Celltrion | Phase 3 | 77 |
| CT-P55 + EU-approved Cosentyx | Celltrion | Phase 3 | 77 |
| AMG 139 | AstraZeneca | Phase 1 | 33 |
| alefacept + polyvalent pneumococcal vaccine | Astellas Pharma | Approved | 85 |
| alefacept | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus Cream | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Phase 3 | 77 |
| peficitinib + Placebo | Astellas Pharma | Phase 2 | 52 |
| Alefacept | Astellas Pharma | Phase 3 | 77 |
| Amevive exposure | Astellas Pharma | Pre-clinical | 23 |
| alefacept + placebo | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Approved | 85 |
| ASKP1240 + Placebo | Astellas Pharma | Phase 2 | 52 |